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Streptococcus pneumoniae is an asymptomatic colonizer of the upper respiratory tract as
well as an opportunistic pathogen. Colonization is prerequisite to causing disease in a host, and it
often involves formation of biofilms. There are currently two vaccines available against
pneumococcus, both of which focus on preventing invasive disease by targeting the
polysaccharide capsule of the most invasive serotypes. We hypothesized that by using membrane
proteins expressed during the biofilm state, we can formulate an effective vaccine against
colonization which would lead to an overall decrease in disease incidence. To do this, we
selected protein candidates expressed during biofilm growth based on their ability to elicit an
IgA response in human serum. Selected proteins (SP_0459, SP_1114, and SP_1702) were
identified and used for further experiments. The proteins identified in this study will be paired
with other immunogenic proteins to determine a successful vaccine formulation targeting
colonization of Streptococcus pneumoniae.
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CHAPTER I
INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is a gram-positive pathogen that is the
leading cause of many noninvasive and invasive pneumococcal diseases (IPD). Noninvasive
infections include otitis media, while pneumonia, bacteremia, and meningitis are invasive forms
of pneumococcal disease. Despite the capacity to cause severe disease, the organism most often
asymptomatically colonizes the mucosal surfaces of the upper respiratory tract in humans.
Carriage rates are highest during the first two years of life, averaging about above 50%, but
declining afterwards (Weiser et al., 2010). Colonization is a key part of pneumococcal
pathogenesis, as disease cannot occur without nasopharyngeal colonization (Berical et al., 2016,
McCool et al., 2002). This colonization is typically asymptomatic (McCool et al., 2002). Once
colonization is established and replication begins, the bacteria can be shed by the host and
transmitted or spread within the host to cause disease. Transmission of bacteria occurs when
infected aerosolized particles are inhaled.
As stated previously, pneumococcal colonization is achieved by adherence to the mucosal
surfaces of the upper respiratory tract. From here, pneumococci can spread to the middle ear,
resulting in otitis media, or disseminate into the blood or lungs, resulting in a severe invasive
disease such as pneumonia, meningitis, or bacteremia. Initial adherence of bacteria occurs upon
inhalation of infected particles and is followed by subsequent formation of a biofilm by
adherence to the epithelium (Sharapova et al., 2021). These biofilms can be interspecific,
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meaning biofilms consisting of multiple different species, or intraspecific, meaning biofilms of
only the same species (Shak et al., 2013). One example of an interspecific biofilm is S. aureus
and S. pneumoniae in the upper respiratory tract. Using both in vitro and in vivo models, one
study demonstrated that upon disruption to these dual-species biofilms, pneumococcus disperses
while S. aureus does not (Reddinger et al., 2018). The benefit of biofilm formation is that it
allows the bacteria an increased resistance to antimicrobials and enhanced ability to evade the
hosts’ immune system (Domenech et al., 2012).
Pneumococcus has been studied in-depth for over a century, but despite extensive
research and vaccine development, colonization rates have remained relatively constant, and
pneumococcal diseases still kill around 800,000 children under the age of 5 every year (Yildirim
et al., 2015). In addition, pneumococcus is able to alter its genome in vivo using exogenous DNA
from other pneumococci or closely related streptococci which leads to capsule switching and
contributes to antibacterial resistance. This burden led the World Health Organization to
categorize Streptococcus pneumoniae as one of the priority pathogens in 2017 (Weiser et al.,
2018). Among adults aged >50 years, there are an estimated 29,500 cases of IPD, 502,600 cases
of pneumonia, and 25,400 pneumococcal-related deaths occur yearly. Total estimated costs for
children under 5, both direct and indirect, adds up to about $1.75 million and $5.3 million,
respectively (Ceyhan et al., 2018). In adults (>19), an estimated cost of $1.8 billion was
attributable to pneumococcal disease in 2015 (Owusu-Edusei et al., 2022).
Two vaccines currently exist for pneumococcal diseases; one is a pneumococcal
polysaccharide (PPSV23) and the other is a pneumococcal conjugate vaccine (PCV13) (Berical
et al., 2016, Paradiso, 2012). While these have undoubtedly decreased the mortality from
pneumococcal disease, shortcomings still exist. Pneumococcus has over 90 different capsule
2

serotypes, and the vaccines only account for 23 (PPSV23) and 13 (PCV13) serotypes,
respectively (Berical et al., 2016). In addition, Prevnar20 was approved for use in 2021.
Prevnar20 is a newer version of the PCV13 that covers 7 additional capsule types. Based on this
trend, it wouldn’t be hard to imagine that scientists will have to continue adding and adjusting
capsule serotypes covered in order to keep up with the evolution of the pathogen. While these
vaccines have been effective, targeting the capsule serotypes may not be the most efficient way
to target pneumococcal disease.
While the pneumococcal polysaccharide vaccine is protective in adults, it fails to protect
the population at the highest risk, young children (McCool et al., 2002). This is because it elicits
a T-cell independent response, which children are less capable of generating. A T-cell
independent response also promotes a short-lived B-cell response and doesn’t promote the
formation of memory B-cells. PPSV23 does not provide an immunological memory response or
eliminate colonization of non-vaccine serotypes which allows for the organism to be passed on to
other individuals (Geno et al., 2015, Sempere et al., 2021). PCV13 is conjugated to diphtheria
toxin, so it provides a stronger immune response that is T cell-dependent, but only against the
serotypes covered by the vaccine. There have been a number of meta-analysis studies to
determine efficacy of the conjugate vaccine (Blasi et al., 2012). While there is conflict over how
exactly to determine this rate, an estimated rate was reported as 74% but this rate did not extend
to the most vulnerable populations as efficiently (Blasi et al., 2012). When considering one of
the high-risk populations, the elderly, the antibodies induced by the vaccine are relatively shortlived and evidence has shown that advancing age and comorbidities attribute to even lower
antibody responses (Papadatou et al., 2016).
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One way to combat the shortcomings of current vaccines is by boosting the response with
an adjuvant. One of the current vaccines, Prevnar, uses the capsular antigens of pneumococcus
with a nontoxic variant of diphtheria toxin (Geno et al., 2015). Other conjugates being studied
include pneumolysin (Ply) toxoid, R3 of PspK, and many choline binding proteins (Sempere et
al., 2021). The issue with some of these targets is that they are a key to pathogenesis of
pneumococcus, but not always involved in colonization or biofilm formation, so antibodies
generated against these antigens may only serve to prevent development of invasive disease. This
would still allow for colonization to occur, and the carrier could pass the bacteria to an
unvaccinated individual.
One of Streptococcus pneumoniae’s most effective virulence factors is the capsule, which
allows it to avoid being targeted by the host immune system and in turn, avoid activating the
complement system and other phagocytic defense mechanisms. The loss of capsule in one
virulent strain caused the virulence to reduce more than one million-fold in a mouse model
(Avery et al., 1931). Because of this importance, the capsule has been extensively studied. As
mentioned, the current vaccines do target the polysaccharide capsule, however, capsule
switching and an increase in non-encapsulated strains are also becoming more prevalent issues
(Sempere et al., 2021). In addition to this capsule, pneumococcus also produces an IgA protease
that cleaves IgA1 molecules into Fc and Fab fragments (Proctor et al., 1990). This cleavage is
done in the hinge region, which is only present in the IgA1 molecules, not found in the IgA2
molecules (Romanello et al., 2006). The activity of this protease is likely an important factor in
the successful colonization of Streptococcus pneumoniae. However, at the mucosal surfaces,
IgA1 and IgA2 are produced in relatively even amounts (Steffen et al., 2020). Based on this
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information, we can still consider IgA as one of the top contributors to fighting against
pneumococcal colonization.
IgA exists in two subclasses in the immune system, IgA1 and IgA2, and occurs in two
physiological forms, serum and secretory. The two forms both occur in the serum and mucosal
tissues but vary in their respective concentrations (Steffen et al., 2020). In the serum, IgA1
occurs in a 9:1 ratio with IgA2 while in the mucosal tissues, they occur more evenly (Steffen et
al., 2020). The other difference between the two forms is the structure of the hinge region and
available glycosylation sites (Steffen et al., 2020).
Secretory IgA has an important role in mediating the adaptive immune response at the
mucosal surfaces where many pathogens gain entry into the body. sIgA is secreted by plasma
cells as polymeric IgA (pIgA), monomeric IgA joined together at the Fc region (Leong et al.,
2014). This pIgA binds to a receptor on the basolateral membrane of epithelial cells and is
transported to the mucosal surfaces as mature sIgA.
Serum IgA functions as an anti-inflammatory molecule to maintain homeostasis (Leong
et al., 2014). While serum IgA has been studied less thoroughly, its importance in pneumococcal
vaccine development could be quite important given the fact that the IgA protease would be
ineffective against it. Some amount of serum IgA is derived from the marginal zone of B-cells
which is home, in part, to B-cells that were activated in the gut-associated lymphoid tissue
(Leong et al., 2014). This would imply that some crossover exists between IgA secreted in the
mucosa and what is circulating in the blood.
When considering a vaccine target, it is important to think about the ability to elicit a
strong immune response, particularly an adaptive, or memory, response. This response is driven
by antigen specific T- and B-cells. For this response to occur at a mucosal surface, IgA needs to
5

be activated. IgA is crucial to the function of the mucosal immune response, and 15% of
immunoglobulin produced is IgA that is secreted into the intestinal lumen (Monteiro et al.,
2003). One study used nasal washes to show that IgA- mice were unable to clear pneumococcal
colonization as efficiently as IgA+ mice though inoculation rates were the same (Lynch et al.,
2003).
We hypothesize that by targeting specific immunogenic proteins, we can produce a
vaccine containing these adjuvant proteins that leads to a thorough IgA response against
pneumococcal colonization. In future trials, these adjuvant proteins will be paired with other
pneumococcal target proteins to formulate a more complete vaccine to reduce colonization of
Streptococcus pneumoniae. The intended vaccine will be an intranasal inoculation which, using
proteins discovered here, will lead to a healthy IgA response. This would lead to an overall
reduction of disease rates and ideally herd immunity for those that cannot get the vaccine
themselves, such as the elderly, very young, and immunocompromised.

6

CHAPTER II
IDENTIFICATION OF PROTEINS OF INTEREST FOR FURTHER STUDY
2.1

Introduction
The first aim of this study was to determine protein candidates that elicit a significant IgA

response. This is particularly important for pneumococcus as one of the current vaccines
available provides little to no IgA response, due to it provoking a T-independent immune
reaction which only leads to the production of IgM. IgA is necessary for the clearance of
pneumococcus since it is the most prevalent immunoglobulin secreted from mucosal surfaces.
This would make it our bodies’ first line of defense against colonization of the respiratory tract.
To do this, we used human serum to probe total pneumococcal protein taken from the biofilm
state to evaluate the extent of the naturally occurring IgA response, as well as identify candidates
that elicit IgA.
Since pneumococcus colonizes in the upper respiratory tract, IgA will be the key to
initiating an effective immune response. Because of this, pneumococcus has developed ways to
evade this immune response from occurring such as the capsule and an IgA protease. It also
produces SpsA which binds to the sIgA and prevents clearance (Wang et al., 2020). If IgA is able
to recognize and react to capsular polysaccharides of pneumococcus, it will lead to complementdependent opsonophagocytosis by phagocytes (Fasching et al., 2002). It also possesses
agglutination ability, which allows the IgA to block the pneumococcus from colonizing, however
this will have negligible impact if colonization has already begun (Lagousi et al., 2020). IgA has
7

also been shown to react to PspA, another pneumococcal surface protein (Fukuyama et al.,
2010). However, while PspA shows less variation among strains than the capsule, it isn’t entirely
conserved (McDaniel et al., 1991). In children, evidence shows that antibodies are mounted
against PsaA and pneumolysin (Zhang et al., 2002). CpbA is another candidate being studied as
both CbpA and PsaA are involved in pneumococcal adherence (Berry et al., 1996, Rosenow et
al., 1992).
Protein analysis was done using 1D Western Blotting and 2D Far-Western analysis and
human serum samples. The intent was to select a number of candidates to identify and use for
further experimental analysis. These candidates could either be novel proteins or previously
identified and studied. By identifying these protein candidates, we could isolate and identify
them and test their effectiveness as immune-boosting adjuvants. From this study, we identified
three proteins of interest that haven’t been studied before as vaccine candidates.
2.2
2.2.1

Methods
Determining presence of an IgA response
Total protein of T4R strain pneumococcus was grown at 34°C overnight in nutrient

limited media (50% THY with chloramphenicol 10µg/mL). This promotes the growth to occur in
a biofilm state. This was run on a 12.5% acrylamide SDS-PAGE gel at varying concentrations to
determine which would be best to use for Western blot analysis. Approximately 5µg of protein
was loaded onto a 12.5% SDS-PAGE gel with ladder and then transferred to a PVDF membrane
for 1 hour at 100V using standard protocol. Once transferred, the membrane was stained with
amido black for marking the molecular weight standards. The membrane was then charged again
with methanol and rinsed with water prior to blotting with human serum for 1 hour shaking at
8

room temp and overnight at -2°C. Human serum was isolated from 9 human individuals of both
sexes and varying ages. Serum samples were diluted 1:10,000 dilution into 3% milk and 1x
PBST. The membrane was washed (900mL of Milli-Q H2O, 100mL of 10x TBS, and 1mL of
Tween20) for 5 minutes. The membrane was then exposed to secondary antibody for 1 hour.
Secondary antibody was a 1:25,000 dilution of either Goat anti-human IgA-HRP or Goat antihuman IgG-HRP in 3% milk in 1x PBST. The blot was then washed 3 times with 1x TTBS
before addition of PICO plus (Thermo Scientific) chemiluminescent substrate before
autoradiography development.
After the initial Western blot analysis, the sample from individual 4 was selected for
further analysis by 2D Western Blotting because of its significant IgA response. Total protein
was loaded and run using a pair of 2D gels and one was transferred to a PVDF membrane. The
other gel was stained with Coomassie blue. Primary antibody used was a 1:10,000 dilution of
serum from individual 4 in 3% milk in 1x PBST, and secondary antibody used was a 1:50,000
dilution of Goat anti-human IgA-HRP in 3% milk in1x PBST and developed as described above.
Three proteins were identified to have a significant response to IgA. These were selected and
sent for mass spectrometry analysis.
The Coomassie stained gel and PVDF membrane were aligned, and the areas of interest
were excised and digested with trypsin (Worthington). Peptide mass spectra were generated
using MALDI-TOF/TOF (ABI4700). Protein identification was done using ABI GPS Explorer
software V3.5. Peptide sequence was analyzed using the SWISS-PROT database in the Mascot
search engine. This was done at the Center of Biomedical Research Excellence “Omics” Core,
which is a part of the Institute for Genomics, Biotechnology, and Biocomputing.
9

2.3

Results
Total biofilm protein was collected and run out on SDS-Page for a 1D analysis (Figure

1). Based on the gel, the 4µg concentration was used as the standard for further experimentation.

Figure 2.1

SDS-Page gel containing standard ladder and samples. Lane 1 shows 5µg of total
biofilm protein loaded. Lane 2 shows 4µg of total biofilm protein loaded

Total protein was exposed to IgA and IgG antibodies and results were visualized by
autoradiography (Figure 2). Based on the 9 individuals, we had varying degrees of response to
the two different antibodies. All individuals mounted some IgG response, but IgA had some
individuals produce no response. Based on our hypothesis, if we are able to boost this IgA
response using a conserved pneumococcal protein, we can minimize the colonization rate of
pneumococcus. This boosted IgA response would also aid in the longevity of a vaccine produced
by mounting a proper memory response.
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Figure 2.2

IgA and IgG serum reactivity from 9 different individuals against pneumococcal
proteins by 1D western blotting analysis.

Based on these results, we further tested the IgA response using Far Western blot 2D gel
analysis. For this purpose, we selected a serum sample with one of the highest IgA responses,
individual 4. This serum was visualized using 2D gel analysis and Far Western blot techniques
(Figure 3). Upon film exposure, the Coomassie stain and the film were scanned for comparison.
Three areas with a particularly strong IgA response were selected as our proteins of interest.
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Figure 2.3

A) Shows the Coomassie stained 2D gel run. B) Shows the Far Western Blot
results after probing with IgA antibodies. C) Shows an overlay image of the two
with the three selected proteins circled.

The three proteins with strong IgA reactivity were excised from the Coomassie gel and
sent to the IGBB for identification by mass spectrometry analysis. The three proteins compared
to the S. pneumoniae TIGR4 protein database and were identified as SP_0459, SP_1114, and
SP_1702. Of these, SP_1702 has been identified as part of the Sec protein translocase complex,
SP_0459 is proposed to be a formate acetyltransferase, and SP_1114 is an ABC transporter ATPbinding protein.
2.4

Discussion
This study is important because robust IgA production is necessary for an efficient

immune response at mucosal surfaces. As shown above, the average IgA reactivity to
pneumococcal proteins in human serum was less than ideal when aiming for protective immunity
and reduced colonization. IgG is the predominant antibody found in the blood, and can be
12

important to preventing invasive disease, IgA will be overall more important in preventing
colonization as it predominates at the mucosal surfaces where pneumococcus colonizes. While it
isn’t certain how much crossover there is between secretory IgA and serum IgA, there is some
evidence to some correlation (Leong et al., 2014). It can also be noted that of the 9 individuals
who donated serum, in general the highest IgA responses were seen in individuals with young
children.
Across all individuals, there was a significantly lower response of IgA vs IgG. While IgG
also plays a role in the humoral immunity, it primarily circulates in the blood which would be
most beneficial to stopping invasive disease. One study showed this importance using a mouse
model (Fukuyama et al., 2010). The study illustrated that IgA deficient mice were able to
produce an antigen-specific response, but they were not able to prevent colonization. The study
concluded that PspA-specific serum IgA played an important role in the prevention of bacterial
colonization in the nasal mucosa (Fukuyama et al., 2010). For the purposes of this study, the
focus is on stopping colonization which will heavily rely on the actions of IgA. The high
colonization rates seen in healthy individuals could be attributed to this lack of a broad IgA
response shown above.
By using isolated biofilm proteins, we focused on potential targets that are likely
expressed during the colonization process within the nasopharynx. The ultimate goal is to use the
proteins identified here in conjunction with other pneumococcal target proteins to create a
multivalent vaccine with the proteins identified here serving as IgA immune boosters. Providing
a sufficient immune response that will activate upon colonization rather than invasive disease,
we hypothesize, will sufficiently lower the colonization rates as well as prevent re-colonization.
13

Though none of the genes identified have been studied as vaccine candidates, there is
some research done on the roles they play in pneumococcus. One study has shown that an
insertion into the SP_0459 gene decreased the fitness levels (van Opijnin et al., 2015). SP_1114
is part of an ABC transporter with SP_1116. SP_1114 is comprised of two ABC domains and
has been shown to be activated by penicillin. Studies also show that mutations in this gene pair
led to an increased susceptibility in antibiotics and a decrease in metabolic activity (Tocci et al.,
2013). SP_1702 works with various other proteins to modify the peptidoglycan brought in during
cell wall synthesis (Engholm et al., 2017). SP_1702 has also been shown to be downregulated
during biofilm growth (Sanchez et al., 2011).
Because all of the selected proteins of interest are membrane proteins, and don’t seem to
play a role in pathogenesis, they would make beneficial adjuvants to a protein-based vaccine. As
evidenced by the current vaccines, the bacteria are able to adapt when certain features are
targeted by acquiring mutations. This is seen in the prevalence of capsule switching. However, if
these membrane proteins are a key to survival of pneumococcus, they may not be altered or lost
at all, or they may be altered at a much slower rate as this will cause a decrease in fitness.
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CHAPTER III
DEVELOPMENT OF AN EXPRESSION SYSTEM FOR PROTEINS OF INTEREST
3.1

Introduction
The goal of this aim was to clone and express our genes of interest in a recombinant

protein expression system. This was done by designing PCR primers for each of our genes so we
could amplify and clone them into our selected vector system. We tested expression in the pOS1
Staphylococcus aureus expression vector and the well-characterized pET system for protein
expression. Issues with cloning and expression with pOS1 led us to focus on the pET vector
system. Each gene was cloned into the pET28a plasmid vector and protein production was
induced by IPTG. We optimized growth conditions to enrich for our proteins in the soluble
fraction of E. coli lysates and verified protein expression by SDS-PAGE analysis.
3.2
3.2.1

Methods
Creating a successful gene insert by PCR
DNA oligonucleotides for genes encoding SP_0459, SP_1114, and SP_1702 were

designed for PCR amplification. All PCR primers used in this project are listed in Table X.
Forward primers contained the BamHI restriction site and reverse primers contained XhoI sites
at their 5’ends for directional cloning into expression vectors. The genes were amplified by PCR
from S. pneumoniae TIGR4 chromosomal DNA template using Ex-Taq DNA polymerase
(Takara) according to the manufacturer’s instructions. Annealing temperatures were determined
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using NEBtm calculator. Amplicons were confirmed positive by agarose gel electrophoresis and
primers removed by DNA Clean and Concentrator kit (Zymo Research).
3.2.2

Combining the insert with a vector through ligation
An overnight culture of E. coli DH5α containing the plasmid pET28a, was grown in

10mL of LB containing 100µL KAN (50µg/ml) at 37°C in a shaking incubator. The overnight
culture was plasmid prepped using Zyppy Plasmid Miniprep Kit (Zymo Research). Inserts were
prepped using the Zymopure DNA Clean and Concentrator-25 kit. The concentrations of all
components were determined by Nanodrop. Both vector and insert were digested overnight in a
37°C water bath with BamHI and XhoI restriction enzymes (New England Biolabs) and
CutSmart buffer. Following digestion, the plasmid treated with calf intestinal phosphatase using
2µL of Quick CIP (New England Biolabs) for 20 minutes in a 37°C water bath. Product was heat
inactivated for 2 minutes at 80°C to stop reaction. The digestions were cleaned and concentrated
again and checked by nanodrop prior to ligation with T4 DNA Ligase, 10x Ligase buffer (New
England Biolabs), water and appropriate concentrations of insert and vector to get a 1:1 and 3:1
ratio (insert:vector). Ligations were incubated at 16°C overnight in thermocycler. Ligations were
heat inactivated at 65°C for 10 minutes and stored at -20°C until transformations.
3.2.3

Transformation into cloning strain of E. coli
Ligations were transformed into chemically competent E. coli DH5α strain. 5µL of

ligation reactions were added to ice-thawed competent cells and mixed gently with the pipette
tip. This mixture was incubated on ice for 30 minutes. Following incubation, cells were heat
shocked at 42°C for 30 seconds and returned to ice. 250µL of SOC media was added to cells and
the tube was placed in the shaking incubator for 1 hour at 37°C. 50µL of each transformation
was pipetted onto a LB plate supplemented with Kanamycin (50µg/mL), spread using L-shaped
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spreaders, and the plates were incubated overnight. Transformants were screened by PCR using
gene-specific primers or T7 primers and confirmed by gel electrophoresis. Colonies were also
plated onto a new LB KAN plate to create a master plate. Successful transformants were selected
for transformation into E. coli BL21 expression strains.
3.2.4

Transformation into expression strain of E. coli
Positively identified DH5α transformants were taken from the master plate and grown

overnight in 5mL of LB with KAN at 37°C in the shaking incubator. 750µL of culture was
mixed with 250µL of 50% glycerol and put into freezer stock culture tubes. 3mL of the
remaining culture was plasmid prepped using Zyppy Plasmid Miniprep kit (Zymo Research)
according to manufacturer’s instructions. Transformation protocol into chemically competent
BL21 followed the same methods as described above for DH5α.Positive transformants were
isolated and frozen down for stocks and used for eventual protein isolation.
3.2.5

Small-Scale inductions of proteins of interest
Small scale induction ofBL21 clones possessing pET28a vector with our genes of interest

were inoculated in 5mL of LB KAN and grown overnight in a shaking incubator at 37°C. The
following day, 50µL of overnight culture was back-diluted into 5mL of fresh LB with KAN in a
50mL conical tube. This was incubated for 3 hours at 37°C in shaking incubator. After 3 hours,
1mL of solution was removed as our uninduced control, 40µL of IPTG was spiked in, and the
conical tube was returned to the incubator for three more hours. Once that incubation was
complete, 1.5mL Eppendorf tubes were used to collect pellets. 1mL of culture centrifuged for 5
minutes at 15,000rpm using a tabletop centrifuge. Supernatant was discarded and pellets were
weighed. A B-per mixture of 1mL B-per, 5ul DNase (1U/µL), and 2uL lysozyme (50mg/mL)
was created and each pellet obtained 4mL of solution per 1g of pellet. Pellets were sonicated for
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30 seconds and sat at room temperature for 15 minutes Tubes were spun down again and
supernatant was moved to a new tube as lysate. 100µL of B-per solution were added to each
pellet and they were sonicated again for 30 seconds. This procedure yields four samples, an
uninduced soluble, uninduced insoluble, induced soluble, and induced insoluble component.
10µL of sample were mixed with 10µL of 2x Loading buffer and boiled for 5 minutes. Results
were visualized by running an SDS-Page gel.
3.2.6

Large Scale inductions of proteins of interest
Large scale inductions were performed similarly to small scale inductions, with the

following modifications. Overnight culture was back-diluted 2mL into 200mL of fresh LB KAN.
For IPTG, 500µL was used, and the incubation following the spike of IPTG was done at 25°C
overnight. The pellet prep protocol was also largely the same but with a sonication of 15 minutes
on ice. Results were confirmed by SDS-PAGE and Coomassie staining.
3.2.7

BCA Assay
BCA assay was performed to determine the exact concentration of protein in our samples.

Samples selected were the third 200mM elution from our 0459 and the 120mM wash for the
1702. Working reagent was created using solutions A and B from the Pierce BCA Assay Kit.
Reagents were prepared so that there was enough to run duplicates of each sample. Unknowns
consisted of a 1:2 and 1:5 dilution of 0459 from the 200mM elution and an undiluted and 1:2
dilution of 1702 from the 120mM wash. In addition, controls were run of the 200mM elution and
120mM wash at the proper dilutions to ensure Imidazole did not interfere with reads. The well
plate was incubated for 30 minutes at 37°C. Plate was read at the 562nm wavelength.
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Once this was determined, samples were diluted as needed so SP_0459 and SP_1702
were at an equal concentration (=.45µg/µl) and 10ul of each sample were mixed with 10µL of
loading dye and all 20µL were run on two SDS-Page gels (12.5% with 5% stacking).
3.2.8

Confirmation of His-Tag and IgA response
One SDS-PAGE gel was stained in Coomassie overnight and destained the following

day. The other gel was transferred to a PVDF membrane for Western blot analysis. This was
done according to our standard protocol. The membrane was exposed to the primary antibody,
Serum sample 4 diluted 1:2000 in 20mL TTBS and 3% milk, for 1 hour on a shaking incubator
and placed at -2°C overnight. The following day, the membrane was washed in TTBS for 5
minutes three times. Following washes, the membrane was probed with secondary antibody, goat
anti-human IgA HRP, for 1 hour on a shaking incubator. Following incubation, membrane was
washed again with TTBS for 5 minutes three times. The membrane was then removed, and PICO
Plus was used to coat membrane. Exposure was done by film.
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3.3

Results

Figure 3.1

PCR Reactions of all three genes of interest. Lane 1 shows standard ladder. Lane 2
shows SP_0459 with an estimated size of 2.6bp. Lane 3 shows SP_1114 with an
estimated size of 2.2bp. lane 4 shows SP_1702 with an estimated size of 2.8bp.

Our PCR and gel electrophoresis confirmed that the primers designed for each protein of
interest worked as well as our Tigr4 template strain. All three genes of interest formed clean
bands at the correct size and could be used as inserts for our vector system (Figure 4). The next
step for the utilization of the vector system was to ligate our insert to our plasmid. Successful
ligations (Figure 5) could be transformed into our first E. coli cloning strain, DH5α. Successful
transformants at this stage would be selected for transformation into our expression strain of E.
coli, BL21 (Figure 6).
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Figure 3.2

Shown above are the successful ligations of each gene. In the case of 1702, the
successful ligation is shown in lane 2.

Figure 3.3

Shown above are the PCR colony screening gels. + signs indicate a positive
transformant
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Upon finding a successful BL21 transformant, we then had to determine our expression
levels of our protein. This was first done by small-scale inductions and results were visualized by
SDS-Page gel.

Figure 3.4

Small scale inductions of SP_0459 and SP_1702.

Based on the results seen in our small-scale induction (Figure 7), we were generally
seeing higher levels of protein expression in the pellet. Based on our gels, we believed the
protein was getting stuck in inclusion bodies, explaining the higher levels of protein in our
insoluble components. Before moving onto large-scale inductions, we optimized our procedures
for overexpression in the soluble component (Figure 8). Protein of interest was present in the
soluble component, but it did not seem to be overexpressing. In Figure 8A which shows a gel of
SP_1702 small-scale induction, the band of the protein of interest does seem to be present, but it
wasn’t producing a dark bank in either component, and the levels in soluble vs insoluble seemed
to be relatively equal. When induction was performed using the smaller amount of IPTG, lower
temperature, longer sonications, and longer incubation time, the results visualized in Figure 8B
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were seen. As shown below, an induction of SP_1702 with these protocols caused the majority
of our protein to be expressed in the soluble fraction, and it was significantly overexpressed
compared to the background proteins in the plasmid.

Figure 3.5

Shows an SDS-Page gel of the inductions using the modified protocol with
SP_0459.

Once proper levels of overexpression were seen in the soluble fraction, large scale
inductions could be performed. Following these inductions, supernatant was run over nickel
affinity chromatography column for His-tag affinity purification (Figure 9). The protocol
followed was developed by Cube Biotech for proteins under native conditions. Following
column purification, there were still contaminating bands present, particularly bands higher than
the protein of interest. The steps taken to troubleshoot this aspect will be discussed further in
Chapter IV.
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Figure 3.6

SDS-Page of large scale inductions of SP_0459 and SP_1702 after His-Tag
Affinity Purification

Since purity of protein was much better than in small-scale inductions, a BCA Assay was
performed. This would determine loading quantities of each sample for an SDS-Page gel to get
each protein at an equal amount. From there, gel would be transferred to PVDF membrane and
exposed to His-Tag and IgA antibodies. Samples selected came from the purest sample identified
by gel (Figure 10).
Once BCA Assay was complete, data was converted to an Excel file to ensure proper
standards. Based on the graph created (Figure 11), our standards were accurate and the
measurements could be trusted.
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Figure 3.7

Column preps for BCA assay. Asterisks indicate which sample was used for BCA
Assay

Figure 3.8

Graph formed by standards

3.4

Discussion
This experiment was important to determine that our proteins of interest could be cloned

and expressed, specifically in the soluble fraction of our expression strain. Gel electrophoresis of
PCR confirmed amplification of correct sized product usingTIGR4 template and Gene-specific
primers. We also had to determine a suitable vector that our gene of interest could be ligated to.
Initially, a Staph aureus vector was tested. Using this system would’ve created secretion
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products clean of endotoxin, a complication involved in using E. coli systems. However, when
our genes were cloned in, we weren’t seeing secretion of the target protein (Figure 12)

Figure 3.9

Shows the Nickel-Column preps from each gene of interest in the S. aureus
RN4220 vector. Eta refers to the vector.

A small-scale induction of SP_1114 in BL21 was also performed, however, based on our
gel, there seemed to be a sequencing error in our protein. All successful transformants were
induced and run on a gel, but a strong band was formed around 50kDa instead of the 76kDa that
we expected to see. The plasmid prep was sent along with aliquots of gene-specific primers to
ASU. Sequencing was done using four samples, all using the plasmid prep prepared from
SP_1114-DH5α. Primers used were T7 forward and reverse, pOS1 forward, and pET28a reverse.
Sequences were run through a ClustalW alignment using BioEdit software along with the
expected sequence to determine error. Unfortunately, the data received back did not give a clear
result as to what, if any, type of mutation occurred. Sequences aligned, but many areas within the
gene were unreadable. It can be assumed that some mutation occurred, but whether it was a
frameshift of single shift causing a premature stop codon, will require additional sequencing.
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CHAPTER IV
PURIFICATION AND ISOLATION OF PROTEINS OF INTEREST
4.1

Introduction
The goal of this portion of our study was to successfully purify our protein candidates.

This step is necessary as the next aim is for an in vivo study. Lysis of our E. coli expression
strains produce a lot of contaminating background proteins, as seen in the inductions from our
previous aim. To be able to successfully evaluate our IgA levels based solely on our proteins of
interest, we needed pure samples to use in vaccination studies. This was done by using His-Tag
purification as well as FPLC chromatography and confirmed by SDS-PAGE gels.
4.2
4.2.1

Methods
Obtaining and preparation of an induced pellet
In order to purify our proteins, we first needed to produce a pellet. This was done by

large scale induction methods. First, using the BL21 freezer stock of our vectors inoculated in
5mL of LB with 50µL of KAN, we grew an overnight culture. The following day, 2mL of
overnight culture was added to 200mL of fresh LB with KAN. This grew at 37°C for 3 hours in a
shaking incubator. Following the 3 hours, 500µL of IPTG was spiked into the media and it was
put back into the shaking incubator for overnight at 25°C. The following day, the culture was
spun down in 50mL conical tubes to produce a pellet. Supernatant was discarded and the pellet
was resuspended in 10mL of binding buffer containing 20mM of imidazole. The mixture was
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then put on ice for 10 minutes and sonicated on ice for 15 minutes. Following sonication, the
culture was loaded into a TOMY spin for 30 minutes at 4C and spun at 15,000rpm. Lysate was
carefully removed and stored until ready for purification.
4.2.2

Purification by Nickel Column
Purification was done using Indigo Ni-NTA agarose by Cube Biotech and a gravity flow

column. The Ni-NTA agarose was loaded into a column previously and stored in ethanol
solution. The solution was allowed to drip out and 5CV of binding buffer was added and allowed
to flow through to condition the column. Once conditioned, the agarose and the lysate were
pipetted up and down and combined in a 10mL conical tube. This was incubated in an end over
end incubator for 1 hour at room temperature. Once the incubation was complete, the solution
was added back into the column and the sample flow through was collected. Binding buffer was
added to the conical tube to remove any remaining resin and return it to the column. The column
was then washed with increasing levels of imidazole, starting with 20mM and going up to
180mM in increments of 20. Each wash was done with 2.5mL of solution, and collected in an
conical tube. The washes were then run on an SDS-Page gel to determine purity levels.
4.2.3

Purification by FPLC
For this protocol, the same procedure as described in the large-scale induction was used

to collect the lysate which could then be loaded into the FPLC.
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4.2.4

BCA Assay
When single bands were identified, fractions 5 of each protein were buffer exchanged to

PBS using PD-10 columns (Cytiva) according to manufacturer’s gravity protocol. These samples
were tested using a BCA Assay to determine protein concentrations present in sample.
4.3

Results
Standard His-Tag Afiinity purification was run using native standard protocol designed

by Cube Biotech. Results showed that a large amount of protein was purified, but contaminating
protein was still present in our samples (Figure 13).

Figure 4.1

Shows the large-scale inductions that were run through nickel column for
attempted purification by His-Tag Affinity.

Since we were not seeing pure protein following the column prep, modifications were
made to the protocol. Cube Biotech calls for 20mM washes followed by 500mM elutions. The
20mM wash seemed to get rid of the bulk of contaminating protein in the first fraction, but very
little was removed in the following wash fractions. The first modification was tested on SP_0459
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and involved using the same wash procedure, but adding two additional elution steps before, one
with 200mM imidazole, a 400mM imidazole, and a 500mM imidazole (Figure 14). Protein was
still contaminated with upper-level bands, and the majority of protein came out from the 200mM
washes. From there, we decided to opt for a slow increase in imidazole starting with the 20mM
wash that was standard to Cube Biotech’s protocol (Figure 15).

Figure 4.2

Shows the modified protocol using varying amounts of imidazole to remove
contaminating protein.
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Figure 4.3

Purification done by Nickel column using the increasing imidazole concentrations
in wash buffer.

Based on the SDS-Page analysis, there was still a fair amount of contamination,
particularly from higher bands. We later discovered that this supposed contamination was
actually due to an error in the loading dye with the beta-mercaptoethanol. However, before this,
we decided to use a more efficient method of purification, fast protein liquid chromatography
(FPLC). Graphs obtained from the Unicorn program can show a visual of which fraction the
highest protein concentration occurs in. We detected a peak around the fifth fraction of SP_0459
and a peak around the fourth elution for SP_1702. Fractions 4-7 of each protein were run on an
SDS-Page gel and Coomassie stained to determine purity levels of protein.
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A)
Figure 4.4

A) Graphs from SP_0459 run through FPLC Unicorn software showing peaks of
protein (blue line) starting in the fifth fraction B) SP_1702 run through FPLC
Unicorn software sowing peaks of protein starting in the fourth fraction
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B)
Figure 4.4 (continued)
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A strong peak was observed in SP_0459 while SP_1702 showed a much narrower peak
(Figure 16). To confirm fractions contained protein, SDS-Page was run. As evidenced, fractions
4-7 all contained of our protein of interest with no contaminating proteins (Figure 17). The most
concentrated protein was buffer exchanged into PBS for vaccination into mice.

Figure 4.5
4.4

FPLC gel images of fractions 4-7 of both proteins.

Discussion
Based on this research, FPLC proved to significantly reduce the contaminating proteins

still present in the standard His-Tag purification protocol. Fractions contained pure protein that
could then be used for immunization trials in mice.
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CHAPTER V
IN VIVO TRIALS TO DETERMINE IGA RESPONSE ELLICITED BY PROTEINS OF
INTEREST
5.1

Introduction
The majority of pneumococcal protein vaccination studies to demonstrate protection have

been conducted in small animals, primarily mice. However, considerable variation between
murine and human immunity are well documented. Therefore, it is important to determine how
closely immunological responses against specific antigens correlate in different hosts. The
purpose of this aim is to determine whether the human serum IgA responses we have identified
as being induced by SP_1702 and SP_0459 carry over to our in vivo study done in laboratory
mice. This was done by running immunization trials with injections of our two recombinant
proteins. Serum samples were taken prior to and post vaccination with individual proteins and
Western Blot analysis was used to determine the antibody response to our proteins of interest.
5.2
5.2.1

Methods
Immunization Trials of Proteins of Interest
Pre-bleeds were taken from mice to establish no IgA response against proteins of interest

prior to vaccination. Purified protein was mixed 1:1 with ImjectAlum (adjuvant). Mice were
injected intrperitoneally with approximately 15µg of SP_1702 or SP_0459. Mice were boosted
twice at two-week intervals with 15µg of recombinant protein. Bleeds were taken again
following approximately 1 week following the second boost. Bleeds were collected in a 1.5mL
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Eppendorf tube, allowed to clot at 4C for 30 min, centrifuged at 5,000rpm in a tabletop
centrifuge, and the clear serum was pipetted out into a new Eppendorf tube. This process was
repeated to ensure only cell-free serum was collected and stored at -20°C.
5.2.2

Analysis of Serum Antibody Response using Western Blotting
Approximately 5µg of purified protein of SP_0459, SP_1702, and Ply was loaded onto a

12.5% SDS-PAGE gel with ladder and then transferred to a PVDF membrane for 1 hour at 100V
using standard protocol. Once transferred, the membrane was stained with amido black for
marking the molecular weight standards. The membrane was then charged again with methanol
and rinsed with water prior to blotting with mouse serum for 1 hour shaking at room temp and
overnight at -2°C. Mouse serum came from either SP_0459 immunized mice, SP_1702
immunized mice, or pre-exposure serum. Serum samples were diluted 1:5,000 into 3% milk and
1x PBST. The membrane was washed (900mL of Milli-Q H2O, 100mL of 10x TBS, and 1mL of
Tween20) for 5 minutes. The membrane was then exposed to secondary antibody for 1 hour.
Secondary antibody was a 1:10,000 dilution of either Goat anti-mouse IgA-HRP or Goat antimouse IgG-HRP in 3% milk in 1x PBST. The blot was then washed 3 times with 1x TTBS
before addition of PICO plus (Thermo Scientific) chemiluminescent substrate before
autoradiography development (Figure 18, 19).
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5.3

Results

Figure 5.1

A) Shows the negative control IgA serum response. B) Shows the IgA serum
response of SP_0459 immunized mice. C) Shows the IgA serum response of
SP_1702 immunized mice.

Figure 5.2

A) Shows the negative control IgG serum response. B) Shows the IgG serum
response of SP_0459 immunized mice. C) Shows the IgG serum response of
SP_1702 immunized mice.
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Western blot analysis was performed using serum from immunized mice and secondary
antibodies to detect production of IgA and IgG. We saw no IgA response against the proteins of
interest. However, the proteins were clearly immunogenic and elicited an IgG response against
each respective protein. As expected, no response was mounted against our negative control
(Ply). It is unknown whether the proteins are unable to induce an IgA response or if the primarily
IgG response is due to the intraperitoneal route of vaccination. Future studies will involve
intranasal immunization with our proteins of interest to see if vaccination route is essential for
IgA induction. Additionally, nasal washes will be performed on the vaccinated mice to determine
if sIgA was induced in the nasopharynx versus serum IgA, which wasn’t detected.
5.4

Discussion
The in vivo trials show that our proteins of interest did not promote an IgA response in

mice. This could have been due to differences in immune responses between humans and mice.
It could also be attributed to inoculation route. One study showed that intranasal inoculation, but
not intramuscular or intraperitoneal injections, led to an established IgA response (Oh et al.,
2021). It’s important to note that the intended method of delivery for the final vaccine
formulation is an intranasal inoculation. Mucosal vaccination has the potential to evoke not only
the mucosal immune system, but also the systemic immune system (Shima et al., 2014). In
contrast, systemic vaccination only provides a sufficient systemic response, and a poor mucosal
response (Shima et al., 2014). Mucosal adjuvants are being studied to find antigens that produce
a well-rounded immune response through mucosal vaccination. One that has been shown to have
some success is the Bacillus anthracis edema toxin when administered via the nasal route
(Boyaka, Prosper N., 2017). These studies found that the induction of Th17 cells were important
in the production of high-affinity IgA (Boyaka, Prosper N., 2017).
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CHAPTER VI
CONCLUSION
Our study found that there are several membrane proteins conserved across
pneumococcal strains that can serve as potential conjugates for a vaccine. Particularly, SP_0459
shows promise, as mutations in this gene can lead to decreases in fitness levels. This tends to
mean the gene is less likely to be lost, even when used as a vaccine target. Interestingly, previous
studies show SP_1702 is downregulated during biofilm growth, but still showed a high response
to IgA. This could also be a promising target if, even at low levels of secretion, we see a
thorough activation of IgA. We discovered that two of these proteins show a significant ability to
promote an IgA response when using human serum samples. This boost in response will
hopefully provide adequate clearance of bacteria and prevention of dissemination. When paired
with other target proteins, it may be possible to prevent colonization altogether by providing an
individual with a memory response to proteins associated with colonization.
However, in our in vivo trials, the results were negative. Our proteins of interest elicited
an IgG response, but not an IgA response. This could be due to many factors, but based on this
study, further research needs to be done to determine validity of the proteins of interest identified
here as potential vaccine candidates.
We also determined a successful protocol for IPTG induction to maximize protein
secretion into the soluble component by breaking up inclusion bodies. By reducing IPTG,
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allowing longer incubation times at lower temperatures, and having a longer sonication step, we
saw a significant increase in the yield levels.
The future aim of this project will be to further study these potential proteins of interest,
and if they are determined to indeed be possible candidates, they will be paired with low
immunogenicity pneumococcal membrane proteins to determine capability of lowering
colonization of pneumococcus. If these proteins prove to be not suitable in producing an IgA
response, other protein candidates can be identified. In the long term, this project will support the
search for a more effective pneumococcal vaccine targeting colonization, and overall lowering
disease and death rates.
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FIGURES
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Figure A.1

SDS-Page gel containing standard ladder and samples. Lane 1 shows 5µg of total
biofilm protein loaded. Lane 2 shows 4µg of total biofilm protein loaded

Figure A.2

IgA and IgG serum reactivity from 9 different individuals against pneumococcal
proteins by 1D western blotting analysis.
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Figure A.3

A) Shows the Coomassie stained 2D gel run. B) Shows the Far Western Blot
results after probing with IgA antibodies. C) Shows an overlay image of the two
with the three selected proteins circled.

Figure A.4

PCR Reactions of all three genes of interest. Lane 1 shows standard ladder. Lane 2
shows SP_0459 with an estimated size of 2.6bp. Lane 3 shows SP_1114 with an
estimated size of 2.2bp. lane 4 shows SP_1702 with an estimated size of 2.8bp.
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Figure A.5

Shown above are the successful ligations of each gene. In the case of 1702, the
successful ligation is shown in lane 2.

Figure A.6

Shown above are the PCR colony screening gels. + signs indicate a positive
transformant
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Figure A.7

Small scale inductions of SP_0459 and SP_1702.

Figure A.8

Shows an SDS-Page gel of the inductions using the modified protocol with
SP_0459.
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Figure A.9

SDS-Page of large-scale inductions of SP_0459 and SP_1702 after His-Tag
Affinity Purification

Figure A.10 Column preps for BCA assay. Asterisks indicate which sample was used for BCA
Assay
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Figure A.11 Graph formed by standards

Figure A.12 Shows the Nickel-Column preps from each gene of interest in the S. aureus
RN4220 vector. Eta refers to the vector.
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Figure A.13 Shows the large-scale inductions that were run through nickel column for
attempted purification by His-Tag Affinity.

Figure A.14 Shows the modified protocol using varying amounts of imidazole to remove
contaminating protein.
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Figure A.15 Purification done by Nickel column using the increasing imidazole concentrations
in wash buffer.
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A)
Figure A.16 A) Graphs from SP_0459 run through FPLC Unicorn software showing peaks of
protein (blue line) starting in the fifth fraction B) SP_1702 run through FPLC
Unicorn software sowing peaks of protein starting in the fourth fraction
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B)
Figure A.16 (continued)
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Figure A.17 FPLC gel images of fractions 4-7 of both proteins.

Figure A.18 A) Shows the negative control IgA serum response. B) Shows the IgA serum
response of SP_0459 immunized mice. C) Shows the IgA serum response of
SP_1702 immunized mice.
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Figure A.19 A) Shows the negative control IgG serum response. B) Shows the IgG serum
response of SP_0459 immunized mice. C) Shows the IgG serum response of
SP_1702 immunized mice.
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